NO20033718L - Syntetiske humane peptider og farmasöytiske sammensetninger omfattende disse for behandling av systemisk lupus erythematosus - Google Patents

Syntetiske humane peptider og farmasöytiske sammensetninger omfattende disse for behandling av systemisk lupus erythematosus

Info

Publication number
NO20033718L
NO20033718L NO20033718A NO20033718A NO20033718L NO 20033718 L NO20033718 L NO 20033718L NO 20033718 A NO20033718 A NO 20033718A NO 20033718 A NO20033718 A NO 20033718A NO 20033718 L NO20033718 L NO 20033718L
Authority
NO
Norway
Prior art keywords
lupus erythematosus
systemic lupus
treatment
pharmaceutical compositions
synthetic human
Prior art date
Application number
NO20033718A
Other languages
English (en)
Other versions
NO331820B1 (no
NO20033718D0 (no
Inventor
Edna Mozes
Original Assignee
Veda Res And Dev Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veda Res And Dev Co Ltd filed Critical Veda Res And Dev Co Ltd
Publication of NO20033718D0 publication Critical patent/NO20033718D0/no
Publication of NO20033718L publication Critical patent/NO20033718L/no
Publication of NO331820B1 publication Critical patent/NO331820B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20033718A 2001-02-26 2003-08-21 Syntetiske humane peptider og peptidpolymerer, anvendelse av disse for fremstilling av farmasoytiske sammensetninger, farmasoytiske sammensetninger for behandling av systemisk lupus erythematosus samt fremgangsmate for a vurdere effekten til et legemiddel inneholdende peptid eller peptidpolymer. NO331820B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL14164701A IL141647A0 (en) 2001-02-26 2001-02-26 Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
PCT/IL2002/000148 WO2002067848A2 (en) 2001-02-26 2002-02-26 PEPTIDES FROM THE 16/6id ANTIBODY FOR TREATING SLE

Publications (3)

Publication Number Publication Date
NO20033718D0 NO20033718D0 (no) 2003-08-21
NO20033718L true NO20033718L (no) 2003-10-09
NO331820B1 NO331820B1 (no) 2012-04-10

Family

ID=11075174

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033718A NO331820B1 (no) 2001-02-26 2003-08-21 Syntetiske humane peptider og peptidpolymerer, anvendelse av disse for fremstilling av farmasoytiske sammensetninger, farmasoytiske sammensetninger for behandling av systemisk lupus erythematosus samt fremgangsmate for a vurdere effekten til et legemiddel inneholdende peptid eller peptidpolymer.

Country Status (29)

Country Link
US (2) US20040127408A1 (no)
EP (1) EP1370575B1 (no)
JP (1) JP4316886B2 (no)
KR (1) KR100860735B1 (no)
CN (1) CN1309733C (no)
AT (1) ATE346094T1 (no)
AU (1) AU2002233618B2 (no)
BR (1) BR0207586A (no)
CA (1) CA2439051C (no)
CR (1) CR7058A (no)
CU (1) CU23276B7 (no)
DE (1) DE60216243T2 (no)
DK (1) DK1370575T3 (no)
EA (1) EA009465B1 (no)
EC (1) ECSP034743A (no)
ES (1) ES2275832T3 (no)
HK (1) HK1059790A1 (no)
HR (1) HRP20030667A2 (no)
HU (1) HU230372B1 (no)
IL (3) IL141647A0 (no)
IS (1) IS6908A (no)
MX (1) MXPA03007622A (no)
NO (1) NO331820B1 (no)
NZ (1) NZ527499A (no)
PL (1) PL373520A1 (no)
PT (1) PT1370575E (no)
SI (1) SI1370575T1 (no)
WO (1) WO2002067848A2 (no)
ZA (1) ZA200305874B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753135B2 (en) * 2000-09-20 2004-06-22 Surromed, Inc. Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
IL141647A0 (en) 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
JP2006516034A (ja) * 2003-01-14 2006-06-15 テバ ファーマシューティカル インダストリーズ リミティド 全身性エリテマトーデスを治療するためのペプチドの非経口製剤
DK1594434T3 (da) * 2003-01-14 2017-01-02 Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US8313950B2 (en) * 2007-05-21 2012-11-20 The Ohio State University Research Foundation Hepcidins as biomarkers for impending lupus nephritis flare
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
KR20140088837A (ko) 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
WO2015051330A1 (en) 2013-10-03 2015-04-09 Oregon Health & Science University RECOMBINANT POLYPEPTIDES COMPRISING MHC CLASS II α1 DOMAINS
WO2018127914A1 (en) 2017-01-05 2018-07-12 Yeda Research And Development Co. Ltd. Peptides for treating sjogren's syndrome
CN112143707A (zh) * 2020-09-29 2020-12-29 广东先康达生物科技有限公司 一种治疗自身免疫细胞的免疫细胞及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127408A (en) * 1872-06-04 Improvement in tooth-powders or dentifrices
US8634A (en) * 1852-01-06 Wool-pickina machine
JPS60184098A (ja) * 1984-03-02 1985-09-19 Suntory Ltd 新規なペプチド及びこれを有効成分とする利尿剤
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5126249A (en) 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
US6066621A (en) * 1989-12-10 2000-05-23 Yeda Research And Development Co. Ltd. Synthetic peptides for the treatment of myasthenia gravis
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9017008D0 (en) 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
US6096878A (en) * 1993-05-10 2000-08-01 Japan Tobacco Inc. Human immunoglobulin VH gene segments and DNA fragments containing the same
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
GB2290293A (en) * 1994-06-08 1995-12-20 Rupert Donald Holms Preparation which inhibits the autoimmune response in HIV, or SLE, patients
US6613536B1 (en) 1995-03-28 2003-09-02 Yeda Research And Development Co. Ltd. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
IL113159A0 (en) * 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US20020054872A1 (en) 1997-03-20 2002-05-09 Yaakov Naparstek Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus
IL120503A0 (en) 1997-03-20 1997-07-13 Hadasit Med Res Service Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
AU1719499A (en) * 1997-12-18 1999-07-05 Boehringer Ingelheim Pharmaceuticals, Inc. Pyridones as src family sh2 domain inhibitors
KR100261262B1 (ko) * 1998-02-03 2000-08-01 윤종용 반도체 습식 설비의 구조 및 이의 로트 로딩/언로딩 방법
US6415877B1 (en) * 1998-07-15 2002-07-09 Deep Vision Llc Subsea wellbore drilling system for reducing bottom hole pressure
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
IL141647A0 (en) 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
DK1594434T3 (da) 2003-01-14 2017-01-02 Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus
JP2006516034A (ja) 2003-01-14 2006-06-15 テバ ファーマシューティカル インダストリーズ リミティド 全身性エリテマトーデスを治療するためのペプチドの非経口製剤

Also Published As

Publication number Publication date
IL157550A0 (en) 2004-03-28
AU2002233618B2 (en) 2006-12-21
IL141647A0 (en) 2002-03-10
SI1370575T1 (sl) 2007-04-30
ZA200305874B (en) 2005-08-31
IS6908A (is) 2003-08-11
EP1370575B1 (en) 2006-11-22
NO331820B1 (no) 2012-04-10
MXPA03007622A (es) 2004-09-14
HRP20030667A2 (en) 2005-06-30
BR0207586A (pt) 2006-11-07
KR20030092004A (ko) 2003-12-03
CU23276B7 (es) 2008-04-09
ECSP034743A (es) 2004-01-28
CN1503806A (zh) 2004-06-09
DK1370575T3 (da) 2007-01-29
IL157550A (en) 2010-05-31
US7858738B2 (en) 2010-12-28
JP2005505493A (ja) 2005-02-24
PL373520A1 (en) 2005-09-05
EA009465B1 (ru) 2007-12-28
JP4316886B2 (ja) 2009-08-19
EA200300939A1 (ru) 2004-12-30
PT1370575E (pt) 2007-01-31
KR100860735B1 (ko) 2008-09-29
CN1309733C (zh) 2007-04-11
EP1370575A4 (en) 2004-09-29
HUP0600778A3 (en) 2012-09-28
CA2439051A1 (en) 2002-09-06
HK1059790A1 (en) 2004-07-16
WO2002067848A3 (en) 2002-12-12
NZ527499A (en) 2005-12-23
HU230372B1 (hu) 2016-03-29
EP1370575A2 (en) 2003-12-17
NO20033718D0 (no) 2003-08-21
DE60216243D1 (de) 2007-01-04
ES2275832T3 (es) 2007-06-16
CA2439051C (en) 2010-02-02
ATE346094T1 (de) 2006-12-15
US20040127408A1 (en) 2004-07-01
WO2002067848A2 (en) 2002-09-06
HUP0600778A2 (en) 2007-01-29
US20080119390A1 (en) 2008-05-22
DE60216243T2 (de) 2007-10-31
CR7058A (es) 2004-11-01

Similar Documents

Publication Publication Date Title
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
CR6425A (es) Anticuerpos monoclonales humanos de ctla-4
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
RS54088B1 (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
NO20033718L (no) Syntetiske humane peptider og farmasöytiske sammensetninger omfattende disse for behandling av systemisk lupus erythematosus
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
EA200201214A1 (ru) Замещенные тиоацетамиды
ECSP034714A (es) Moleculas de enlace terapeuticas
DK1409544T3 (da) Humane DR4-antistoffer og anvendelser deraf
BRPI0406802A (pt) Derivados de 9-cetoespinosinas
CY1115969T1 (el) Διαδικασια για συμπυκνωση αντισωματων και θεραπευτικων προϊοντων αυτων
RU2003109357A (ru) Лекарственное средство для лечения болезней суставов

Legal Events

Date Code Title Description
MK1K Patent expired